Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tatiana A. Laidus"'
Autor:
Fedor V. Moiseyenko, Ekaterina S. Kuligina, Albina S. Zhabina, Sergey A. Belukhin, Tatiana A. Laidus, Aleksandr S. Martianov, Kirill A. Zagorodnev, Tatyana N. Sokolova, Svetlana A. Chuinyshena, Maxim M. Kholmatov, Elizaveta V. Artemieva, Ekaterina O. Stepanova, Tatiana N. Shuginova, Nikita M. Volkov, Grigoriy A. Yanus, Evgeny N. Imyanitov
Publikováno v:
International Journal of Clinical Oncology. 27:850-862
This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs).Serial plasma samples were collected from 30 pa
Autor:
Ekaterina Sh Kuligina, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Evgeny N. Imyanitov, Aleksandr S. Martianov, Tatiana A. Laidus
Publikováno v:
Problems in oncology. 67:593-599
Until recently, the establishment of a universal test, allowing the early cancer detection by the analysis of blood, urine or other biological fluids seemed as realistic as the development of "Perpetuum mobile". There are numerous obstacles on this r
Autor:
Tatiana A. Laidus, Tatyana N. Sokolova, Nikita M. Volkov, A S Zhabina, Maxim M. Kholmatov, Fedor Moiseenko, Ekaterina Sh Kuligina, Vladislav Turin, Aleksandr S. Martianov, Sergey Beluhin, Grigoiy Yanus
Publikováno v:
Problems in oncology. 67:665-674
This study aimed to analyze changes in the plasma concentration of EGFR-mutated DNA occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). The study included 30 patients with EGFR mutation-driven non-small cell
Autor:
Tatyana N. Sokolova, Olga S. Yatsuk, Roman Meerovich, Kirill A. Zagorodnev, Evgeny N. Imyanitov, Maxim M. Kholmatov, Grigoriy A. Yanus, Olga A. Zaitseva, Ekaterina Sh Kuligina, Maria O. Anisimova, Tatiana A. Laidus, Aleksandr S. Martianov, Aleksandr A. Romanko
Publikováno v:
Cancer Genetics. :165-178
Purpose This study aimed to investigate factors, which influence the content of circulating tumor DNA (ctDNA). Methods 398 serial plasma samples were collected within 1–7 consecutive days from patients with EGFR-mutated lung cancer (n = 13), RAS/RA
Autor:
Natalia V. Mitiushkina, Grigory A. Yanus, Ekatherina Sh. Kuligina, Tatiana A. Laidus, Alexandr A. Romanko, Maksim M. Kholmatov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Evgeny N. Imyanitov
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 9; Pages: 4586
DNA from formalin-fixed paraffin-embedded (FFPE) tissues, which are frequently utilized in cancer research, is significantly affected by chemical degradation. It was suggested that approaches that are based on duplex sequencing can significantly impr
Autor:
Maxim M. Kholmatov, Tatiana A. Laidus, Grigoriy Yanus, Kirill A. Zagorodnev, T. V. Sokolova, O. Vlasova, Alexandr A. Romanko, Vladislav Tyurin, Ekatherina Sh. Kuligina, Roman Meerovich, Aleksandr Martyanov, Maria O. Anisimova
Publikováno v:
Problems in oncology. 66:391-397
«Liquid biopsy» is gradually becoming a mandatory procedure in cancer diagnostics. The aim of this procedure is to detect and monitor tumor-specific markers in various body fluids (blood, urine, pleural fluid, etc.). Significant efforts have been m
Autor:
Igor E. Orlov, Tatiana A. Laidus, Anastasia V. Tumakova, Grigoriy A. Yanus, Aglaya G. Iyevleva, Anna P. Sokolenko, Ilya V. Bizin, Evgeny N. Imyanitov, Evgeny N. Suspitsin
Publikováno v:
European Journal of Medical Genetics. 65:104426
Whole exome sequencing (WES) is a powerful tool for the cataloguing of population-specific genetic diseases. Within this proof-of-concept study we evaluated whether analysis of a small number of individual exomes is capable of identifying recurrent p
Autor:
Tatyana N. Sokolova, Tatiana A. Laidus, Ekaterina Sh Kuligina, Kirill A. Zagorodnev, Grigoriy A. Yanus, Maxim M. Kholmatov, Roman Meerovich, Evgeny N. Imyanitov, Aleksandr S. Martianov, Maria O. Anisimova
Publikováno v:
Cancer Research. 80:717-717
Liquid biopsy is potentially useful for early tumor detection, monitoring of cancer disease during treatment and diagnosis of therapy-related secondary mutations. Despite significant advantages, it cannot be routinely used in cancer medicine until th